These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 33757440)

  • 21. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
    Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
    Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
    Front Oncol; 2020; 10():41. PubMed ID: 32083002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
    Katz MH; Shi Q; Ahmad SA; Herman JM; Marsh Rde W; Collisson E; Schwartz L; Frankel W; Martin R; Conway W; Truty M; Kindler H; Lowy AM; Bekaii-Saab T; Philip P; Talamonti M; Cardin D; LoConte N; Shen P; Hoffman JP; Venook AP
    JAMA Surg; 2016 Aug; 151(8):e161137. PubMed ID: 27275632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
    Fietkau R; Grützmann R; Wittel UA; Croner RS; Jacobasch L; Neumann UP; Reinacher-Schick A; Imhoff D; Boeck S; Keilholz L; Oettle H; Hohenberger WM; Golcher H; Bechstein WO; Uhl W; Pirkl A; Adler W; Semrau S; Rutzner S; Ghadimi M; Lubgan D
    Strahlenther Onkol; 2021 Jan; 197(1):8-18. PubMed ID: 32914237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
    Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
    BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis.
    Yoo C; Lee SS; Song KB; Jeong JH; Hyung J; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Lee SS; Kim JH; Jin HS; Park JH; Hwang DW; Lee JH; Lee W; Chang HM; Kim KP; Ryoo BY; Kim SC
    Br J Cancer; 2020 Aug; 123(3):362-368. PubMed ID: 32433600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
    Schwarz L; Vernerey D; Bachet JB; Tuech JJ; Portales F; Michel P; Cunha AS
    BMC Cancer; 2018 Jul; 18(1):762. PubMed ID: 30041614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma.
    Acuna-Villaorduna A; Shankar V; Wysota M; Jirgal A; Kabarriti R; Bellemare S; Goldman I; Kaubisch A; Aparo S; Goel S; Chuy J
    Cancer Control; 2022; 29():10732748221134411. PubMed ID: 36221952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
    JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
    van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
    JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
    Yamaguchi J; Yokoyama Y; Fujii T; Yamada S; Takami H; Kawashima H; Ohno E; Ishikawa T; Maeda O; Ogawa H; Kodera Y; Nagino M; Ebata T
    Ann Surg; 2022 Jun; 275(6):1043-1049. PubMed ID: 35258510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
    Ingram MA; Lauren BN; Pumpalova Y; Park J; Lim F; Bates SE; Kastrinos F; Manji GA; Kong CY; Hur C
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1565. PubMed ID: 35122419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials.
    Moretto R; Vetere G; Carullo M; Ciracì P; Masi G; Cremolini C
    Cancer Treat Rev; 2024 Nov; 130():102829. PubMed ID: 39305700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
    Katz MHG; Shi Q; Meyers J; Herman JM; Chuong M; Wolpin BM; Ahmad S; Marsh R; Schwartz L; Behr S; Frankel WL; Collisson E; Leenstra J; Williams TM; Vaccaro G; Venook A; Meyerhardt JA; O'Reilly EM
    JAMA Oncol; 2022 Sep; 8(9):1263-1270. PubMed ID: 35834226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
    Suker M; Beumer BR; Sadot E; Marthey L; Faris JE; Mellon EA; El-Rayes BF; Wang-Gillam A; Lacy J; Hosein PJ; Moorcraft SY; Conroy T; Hohla F; Allen P; Taieb J; Hong TS; Shridhar R; Chau I; van Eijck CH; Koerkamp BG
    Lancet Oncol; 2016 Jun; 17(6):801-810. PubMed ID: 27160474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives.
    Mas L; Schwarz L; Bachet JB
    Curr Opin Oncol; 2020 Jul; 32(4):356-363. PubMed ID: 32541325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.